Abstract
This chapter discusses the recommended storage conditions of prequalified vaccines. First, data from the literature on heat and freeze stability are summarized and explained. Next, an excursus provides current information on the shelf life and storage requirements of COVID-19 vaccines. Then, the challenge of cold storage and its importance in vaccine distribution is discussed. Finally, a vision for an ideal vaccine is outlined, and potential improvements are identified.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
AboulFotouh K, Cui Z, Williams RO (2021) Next-generation COVID-19 vaccines should take efficiency of distribution into consideration. AAPS PharmSciTech 22:126. https://doi.org/10.1208/s12249-021-01974-3
Al-Halifa S, Gauthier L, Arpin D et al (2019) Nanoparticle-based vaccines against respiratory viruses. Front Immunol 10:1–11. https://doi.org/10.3389/fimmu.2019.00022
Arpagaus C (2018) pharmaceutical particle engineering via nano spray drying—process parameters and application examples on the laboratory-scale. Int J Med Nano Res 5. https://doi.org/10.23937/2378-3664.1410026
Arpagaus C (2019) PLA/PLGA nanoparticles prepared by nano spray drying. J Pharm Investig 1–22. https://doi.org/10.1007/s40005-019-00441-3
Arpagaus C, John P, Collenberg A, Rütti D (2017) Nanocapsules formation by nano spray drying. In: Jafari SM (ed) Nanoencapsulation technologies for the food and nutraceutical industries. Elsevier, pp 346–401
Arpagaus C, Collenberg A, Rütti D et al (2018) Nano spray drying for encapsulation of pharmaceuticals. Int J Pharm 546:194–214. https://doi.org/10.1016/j.ijpharm.2018.05.037
BIONITY (2004) Braking the cold chain: a new technology based on processes two billion years old promises to revolutionise the international vaccine programme, 21.10.2004. In: Bionity.com, News. https://www.bionity.com/en/news/40384/ ©LUMITOS AG
Callaway E (2020) The race for coronavirus vaccines: a graphical guide. Nature 580:576–577. https://doi.org/10.1038/d41586-020-01221-y
Cavalier G (2020) The cold chain: a logistical challenge at the heart of the distribution of the COVID-19 vaccine. https://iifiir.org/en/news, https://iifiir.org/en/news/the-cold-chain-a-logistical-challenge-at-the-heart-of-the-distribution-of-the-covid-19-vaccine
Cavalier G, Fertel C, De Paoli F et al (2021) Cold chain technology brief: vaccines
Chen D, Kristensen D (2009) Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines 8:547–557. https://doi.org/10.1586/erv.09.20
Chen D, Kapre S, Goel A et al (2010) Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method. Vaccine 28:5093–5099. https://doi.org/10.1016/j.vaccine.2010.04.112
Crommelin DJA, Anchordoquy TJ, Volkin DB et al (2021) Addressing the cold reality of mRNA vaccine stability. J Pharm Sci 110:997–1001. https://doi.org/10.1016/j.xphs.2020.12.006
Cui F (2020) Strategies to increase timely uptake of hepatitis B vaccine birth dose. Lancet Glob Heal 8:e869–e870. https://doi.org/10.1016/S2214-109X(20)30257-6
CureVac (2020a) Clinical trial protocol, COVID-19: a phase 2b/3, Randomized, observer-blinded, placebo-controlled, multicenter clinical study evaluating the efficacy and safety of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and older, 11 Nov. 1–152
CureVac (2020b) CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics. Press Release, 12 Nov 2020
CureVac (2021) Press Release, 12 Oct 2021, CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology. https://www.curevac.com/en/2021/10/12/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technology/
Das P (2004) Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis 4:719. https://doi.org/10.1016/S1473-3099(04)01222-8
Das S (2020) ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman, 12 Dec 2020. Bus.Stand. https://www.business-standard.com/article/current-affairs/zycov-d-shot-can-remain-stable-at-room-temperature-zydus-cadila-chairman-120121200544_1.html
Dunn A (2020) Pfizer’s top scientist tells us the pharma giant is already thinking about a new version of its coronavirus vaccine for 2021 that can overcome one of its biggest limitations, 19 Nov 2020. Bus.Insid. https://www.businessinsider.com/pfizer-is-developing-powder-version-of-its-covid-19-vaccine-2020-11
FDA (2022) Vaccines licensed for use in the United States, Content current as of 31 Jan 2022. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states
GAVI (2020) The vaccine innovation prioritisation strategy. https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy
Hanson CM, George AM, Sawadogo A, Schreiber B (2017) Is freezing in the vaccine cold chain an ongoing issue? A literature review. Vaccine 35:2127–2133. https://doi.org/10.1016/j.vaccine.2016.09.070
Heida R, Hinrichs WLJ, Frijlink HW (2021) Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev Vaccines 00:1–18. https://doi.org/10.1080/14760584.2021.1903878
Ivanova P, Sagdiev R (2020) Exclusive: Russia focuses on freeze-dried vaccine doses as transport fix, 15 Nov 2020. In: Reuters
Jackson T, Peterson G, Naunton M et al (2018) Over half of vaccines are wasted globally for these simple reasons. In: World Econ. Forum. https://www.weforum.org/agenda/2018/07/the-biggest-hurdle-to-universal-vaccination-might-just-be-a-fridge
Jain S, Batra H, Yadav P, Chand S (2020) COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines 8:649. https://doi.org/10.3390/vaccines8040649
Jusu MO, Glauser G, Seward JF et al (2018) Rapid establishment of a cold chain capacity of—60 °C or colder for the STRIVE ebola vaccine trial during the ebola outbreak in sierra leone. J Infect Dis 217:S48–S55. https://doi.org/10.1093/infdis/jix336
Kaddar M, Schmitt S, Makinen M, Milstien J (2013) Global support for new vaccine implementation in middle-income countries. Vaccine 31:B81–B96. https://doi.org/10.1016/j.vaccine.2012.11.085
Kahn A-L (2019) An update on the WHO work in support of the controlled temperature chain (CTC), September 2019. In: UNICEF Vaccine Ind. Consult. Sept 2019. https://www.unicef.org/supply/media/3216/file/VIC-2019-Session-6-Pres-3-CTCupdate.pdf
Kahn A-L, Kristensen D, Rao R (2017) Extending supply chains and improving immunization coverage and equity through controlled temperature chain use of vaccines. Vaccine 35:2214–2216. https://doi.org/10.1016/j.vaccine.2016.10.091
Kartoglu U, Milstien J (2014) Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines 13:843–854. https://doi.org/10.1586/14760584.2014.923761
Kols A, Sherris J (2000) HPV Vaccines: promise and challenges, July 2000. PATH
Kristensen D, Chen D (2010) Stabilization of vaccines: lessons learned. Hum Vaccin 6:227–231. https://doi.org/10.4161/hv.6.3.11618
Kristensen D, Chen D, Cummings R (2011) Vaccine stabilization: research, commercialization, and potential impact. Vaccine 29:7122–7124. https://doi.org/10.1016/j.vaccine.2011.05.070
Kristensen DD, Bartholomew K, Villadiego S, Lorenson K (2016a) What vaccine product attributes do immunization program stakeholders value? Results from interviews in six low- and middle-income countries. Vaccine 34:6236–6242. https://doi.org/10.1016/j.vaccine.2016.10.057
Kristensen DD, Lorenson T, Bartholomew K, Villadiego S (2016b) Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries. Vaccine 34:899–904. https://doi.org/10.1016/j.vaccine.2016.01.001
Kumru OS, Joshi SB, Smith DE et al (2014) Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals 42:237–259. https://doi.org/10.1016/j.biologicals.2014.05.007
Kunda NK, Wafula D, Tram M et al (2016) A stable live bacterial vaccine. Eur J Pharm Biopharm 103:109–117. https://doi.org/10.1016/j.ejpb.2016.03.027
Kurzątkowski W, Kartoğlu Ü, Staniszewska M et al (2013) Structural damages in adsorbed vaccines affected by freezing. Biologicals 41:71–76. https://doi.org/10.1016/j.biologicals.2011.10.011
Lee BY, Cakouros BE, Assi T-M et al (2012) The impact of making vaccines thermostable in Niger’s vaccine supply chain. Vaccine 30:5637–5643. https://doi.org/10.1016/j.vaccine.2012.06.087
Levin A, Levin C, Kristensen D, Matthias D (2007) An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh. Vaccine 25:6945–6957. https://doi.org/10.1016/j.vaccine.2007.06.065
Levine MM (2011) “IDEAL” vaccines for resource poor settings. Vaccine 29:D116–D125. https://doi.org/10.1016/j.vaccine.2011.11.090
Lloyd J (2000) Technologies for vaccine delivery in the 21st century, WHO/V&B/00.35, December 2000
Logunov DY, Dolzhikova IV, Zubkova OV et al (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396:887–897. https://doi.org/10.1016/S0140-6736(20)31866-3
Lydon P, Zipursky S, Tevi-Benissan C et al (2014) Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull World Health Organ 92:86–92. https://doi.org/10.2471/BLT.13.123471
Manufacturing Chemist (2010) No need for the cooler, 6 Sept 2010. www.manufacturingchemist.com
Matthias DM, Robertson J, Garrison MM et al (2007) Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 25:3980–3986. https://doi.org/10.1016/j.vaccine.2007.02.052
McGill COVID19 Vaccine Tracker Team (2021) COVID-19 vaccine tracker. Accessed on 5 Jan 2021. https://covid19.trackvaccines.org/types-of-vaccines/
Moderna (2020) Fact sheet for healthcare providers administring vaccine (vaccination providers) emergency use authorization (EUA) of the moderna COVID-19 vaccine to prevent corona virus disease 2019 (COVID-19) in individuals 18 years of age and older, pp 1–5
MSF (2014) Médecins Sans Frontières Access Campaign, Vaccinating Children Beyond The Cold Chain, Issue Brief, 29 April 2019, pp 1–12
Murhekar MV, Dutta S, Kapoor AN et al (2013) Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states. Bull World Health Organ 91:906–913. https://doi.org/10.2471/BLT.13.119974
Mvundura M, Lydon P, Gueye A et al (2017) An economic evaluation of the controlled temperature chain approach for vaccine logistics: evidence from a study conducted during a meningitis A vaccine campaign in Togo. Pan Afr Med J 27:27. https://doi.org/10.11604/pamj.supp.2017.27.3.12087
Odevall L, Hong D, Digilio L et al (2018) The Euvichol story—development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. Vaccine 36:6606–6614. https://doi.org/10.1016/j.vaccine.2018.09.026
Ohtake S, Martin RA, Yee L et al (2010) Heat-stable measles vaccine produced by spray drying. Vaccine 28:1275–1284. https://doi.org/10.1016/j.vaccine.2009.11.024
Otto BF, Suarnawa IM, Stewart T et al (1999) At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 18:498–502. https://doi.org/10.1016/S0264-410X(99)00242-X
Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17:261–279. https://doi.org/10.1038/nrd.2017.243
Patel MK, Kahn AL (2018) Game changing: hepatitis B vaccine in a controlled temperature chain. Lancet Glob Heal 6:e596–e597. https://doi.org/10.1016/S2214-109X(18)30233-X
PATH (2003) Evidence of vaccine freezing in the cold chain, literature review
PATH (2009) Intradermal delivery of vaccines, a review of the literature and the potential for development for use in low- and middle_income countries, 27 Aug 2009. https://www.who.int/immunization/programmes_systems/supply_chain/optimize/Intradermal-delivery-vaccines_report_2009-Sept.pdf
PATH (2012) Summary of stability data for licensed vaccines, 29 Nov 2012, produced by Working in Tandem, Ltd. for PATH
PATH (2020) Beyond the syringe—vaccine formulation, explained, How drops, shots, and powders could make a COVID-19 vaccine available to everyone, 20 Nov 2020. https://www.path.org/articles/beyond-the-syringevaccine-formulation-explained/
PATH/WHO (2012) Fact sheet—optimize—immunization systems and technologies for tomorrow—taking advantage of the true heat stability of vaccines
Petit D, Tevi-Benissan C, Woodring J et al (2017) Countries’ interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions. Vaccine 35:6866–6871. https://doi.org/10.1016/j.vaccine.2017.10.025
Pfizer (2021a) EMA approves new storage option for pfizer-biontech vaccine, easing distribution and storage of doses across european union, 26 March 2021. https://www.pfizer.com/news/press-release/press-release-detail/ema-approves-new-storage-option-pfizer-biontech-vaccine
Pfizer (2021b) Study to evaluate the safety, tolerability, and immunogenicity of multiple formulations of BNT162B2 against COVID-19 in healthy adults, ClinicalTrials.gov Identifier: NCT04816669. https://www.pfizer.com/science/find-a-trial/nct04816669
Pfizer-BioNTech (2020) Fact sheet for healthcare providers administring vaccine, emergency use authorization (EUA) of the pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older, pp 1–6
RDIF (2020) Sputnik V, general information. The Russian Direct Investment Fund (RDIF). https://sputnikvaccine.com/about-vaccine/
Rigby J (2020) How a deep-frozen vaccine reached 400,000 people helped stop Ebola and holds hope for coronavirus, 15 Nov 2020. TheTelegraph. https://www.telegraph.eo.uk/global-health/science-and-disease/deep-frozen-vaccine-reached-400000-people-helped-stop-ebola/
Scott N, Palmer A, Morgan C et al (2018) Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. Lancet Glob Heal 6:e659–e667. https://doi.org/10.1016/S2214-109X(18)30219-5
Seaman CP, Morgan C, Howell J et al (2020) Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. Lancet Glob Heal 8:e931–e941. https://doi.org/10.1016/S2214-109X(20)30231-X
Shank-Retzlaff ML, Zhao Q, Anderson C et al (2006) Evaluation of the thermal stability of Gardasil®. Hum Vaccin 2:147–154. https://doi.org/10.4161/hv.2.4.2989
Taher M, Shaari SS, Susanti D (2021) Potential nanospray inhalation of remdesivir and hydroxychloroquine using poly (lactic-co-glycolic) acid as fast delivery for Covid-19 treatment. J Pharm 1:34–44. https://doi.org/10.31436/jop.v1i1.50
UNICEF (2019) Supply annual report 2019, pp 1–65
UNICEF (2021) COVID-19 vaccine market dashboard. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard
Uwagbale E-E (2020) A successful Ebola vaccine delivery shows how a Covid-19 vaccine would work in Africa, 23 Nov 2020. QUARTZ AFRICA. https://qz.com/africa/1936803/ebola-vaccine-delivery-shows-how-covid-vaccine-can-work-in-africa/
VIPS (2019) VIPS Phase I executive summary: heat-stable/controlled temperature chain (CTC) qualified dry formulations (vaccine innovation prioritisation strategy), pp 1–7
VIPS (2020a) The VIPS prioritisation process: methodology and outcomes (vaccine innovation prioritisation strategy), pp 1–24
VIPS (2020b) VIPS phase II executive summary: heat stable/controlled temperature chain (CTC) qualified liquid formulations (vaccine innovation prioritisation strategy), pp 1–16
Wang J, Peng Y, Xu H et al (2020) The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech 21:225. https://doi.org/10.1208/s12249-020-01744-7
WHO (2002) Getting started with vaccine vial monitors. Tech. Sess. Vaccine Vial Monit. 27 March 2002, Geneva, pp 1–17
WHO (2005) Monitoring vaccine wastage at country level, Guidelines for programme managers, WHO/V&B/03.18.Rev.1
WHO (2006a) Guidelines on stability evaluation of vaccines, WHO/BS/0.6.2049
WHO (2006b) Temperature sensitivity of vaccines, WHO/IVB/06.10, August 2006. World Heal Organ Dep Immunization, Vaccines Biol 1–58. WHO/IVB/06.10
WHO (2012) Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain. Newsroom, 14 Nov 2012, Atalanta. https://www.who.int/immunization/newsroom/menafrivac_20121114/en/
WHO (2013) Use of MenAfriVacTM (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns, WHO/IVB/13.04
WHO (2015a) Module 2: the vaccine cold chain. WHO 1–46
WHO (2015b) How to monitor temperatures in the vaccine supply chain, WHO/IVB/15.04. WHO Vaccine Manag. Handbook, Modul. VMH-E2-01.1 1–44
WHO (2015c) Assessing the programmatic suitability of vaccine candidates for WHO prequalification (Revision 2014), WHO/IVB/14.10, January 2015
WHO (2016a) Annex 5 guidelines on the stability evaluation of vaccines for use under extended controlled temperature conditions. WHO Tech Rep Ser No 999, 2016. WHO/BS/2015.2268
WHO (2016b) A systematic review of monovalent hepatitis B vaccine thermostability
WHO (2017) Controlled Temperature Chain: Strategic Roadmap for Priority Vaccines 2017–2020, WHO/IVB/17.20 (Orginally distributed as WHO/IVB/17.17)
WHO (2018) Global Vaccine Action Plan, Monitoring, Evaluation & Accountability, Secretariat Annual Report 2018
WHO (2020) Controlled temperature chain page website. http://www.who.int/immunization/programmes_systems/supply_chain/ctc/en
WHO (2021a) Vaccine safety basics e-learing course, module 2: types of vaccines and adverse reactions, route of administration. https://vaccine-safety-training.org/route-of-administration.html
WHO (2021b) WHO prequalified vaccines, online database: https://extranet.who.int/gavi/PQ_Web. Accessed on 20 March 2021. https://extranet.who.int/gavi/PQ_Web
WHO (2021c) Draft landscape of COVID-19 candidate vaccines, 24 Dec 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
WHO (2021d) WHO coronavirus disease (COVID-19) dashboard. Accessed on 13 June 2021. https://covid19.who.int/
WHO (2021e) Therapeutics and COVID-19, living guideline, 31 March 2021e, pp 1–60
WHO/PATH (2013) Delivering MenAfriVAC using the controlled temperature chain approach, project optimize
WHO/PATH (2014) Temperature sensitivity of vaccines, March 2014
Wouters OJ, Shadlen KC, Salcher-Konrad M et al (2021) Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397:1023–1034. https://doi.org/10.1016/S0140-6736(21)00306-8
Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269. https://doi.org/10.1038/s41586-020-2008-3
Zaffran M, Vandelaer J, Kristensen D et al (2013) The imperative for stronger vaccine supply and logistics systems. Vaccine 31:B73–B80. https://doi.org/10.1016/j.vaccine.2012.11.036
Zhu C, Shoji Y, McCray S et al (2014) Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up. Pharm Res 31:3006–3018. https://doi.org/10.1007/s11095-014-1394-3
Zimmer C, Corum J, Sui-Lee W (2021) Coronavirus vaccine tracker. Accessed on 5 Jan 2021. New York Times. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Zipursky S, Djingarey MH, Lodjo J-C et al (2014) Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 32:1431–1435. https://doi.org/10.1016/j.vaccine.2014.01.038
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Arpagaus, C. (2023). Thermostability of Vaccines. In: Spray Drying of Vaccines. Springer, Cham. https://doi.org/10.1007/978-3-031-24323-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-24323-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-24322-6
Online ISBN: 978-3-031-24323-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)